Fejka Martin, Dixon Simon R, Safian Robert D, O'Neill William W, Grines Cindy L, Finta Bohuslav, Marcovitz Pamela A, Kahn Joel K
Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan 48073, USA.
Am J Cardiol. 2002 Dec 1;90(11):1183-6. doi: 10.1016/s0002-9149(02)02831-x.
Cardiac tamponade is an uncommon but life-threatening complication of percutaneous coronary intervention (PCI). The purpose of the present study was to characterize the incidence, management, and clinical outcome associated with this complication. We analyzed a prospective database of 25,697 PCIs performed at William Beaumont Hospital (Royal Oak, Michigan) between October 1993 and December 2000. Cardiac tamponade was observed in 31 of 25,697 PCI procedures (0.12%). Cardiac tamponade was diagnosed in the catheterization laboratory in 17 of 31 patients (55%), and 14 patients (45%) had a delayed presentation (mean time from PCI 4.4 hours). Cardiac tamponade was twice as frequent after use of atheroablative devices compared with percutaneous transluminal coronary angioplasty and stenting (0.26% vs 0.11%, p <0.05). All patients with immediate cardiac tamponade had coronary artery perforation. In 11 of 14 patients with delayed tamponade (79%), no actual site of perforation could be identified. A moderate or large pericardial effusion was observed in 20 patients, and 9 had small effusions without typical echocardiographic features of tamponade. Pericardiocentesis was performed in 30 patients; 19 patients (61%) were treated successfully with aspiration alone, but 12 patients (39%) required further emergency surgical intervention. In-hospital complications included death (42%), emergency surgery (39%), myocardial infarction (29%), and transfusion (65%). Cardiac tamponade is an uncommon but important complication of PCI and is associated with high mortality and morbidity. Most cases are recognized in the catheterization laboratory, but delayed cardiac tamponade may occur and must be considered as a cause of late hypotension after PCI.
心脏压塞是经皮冠状动脉介入治疗(PCI)中一种罕见但危及生命的并发症。本研究的目的是描述与该并发症相关的发生率、处理方法及临床结局。我们分析了1993年10月至2000年12月在威廉·博蒙特医院(密歇根州皇家橡树)进行的25697例PCI的前瞻性数据库。在25697例PCI手术中有31例(0.12%)观察到心脏压塞。31例患者中有17例(55%)在导管室被诊断为心脏压塞,14例患者(45%)出现延迟表现(从PCI开始的平均时间为4.4小时)。与经皮腔内冠状动脉成形术和支架置入术相比,使用粥样斑块消融装置后心脏压塞的发生率高出两倍(0.26%对0.11%,p<0.05)。所有即刻发生心脏压塞的患者均有冠状动脉穿孔。14例延迟性心脏压塞患者中有11例(79%)无法确定实际穿孔部位。20例患者观察到中量或大量心包积液,9例有少量积液但无心脏压塞的典型超声心动图特征。30例患者进行了心包穿刺;19例患者(61%)仅通过抽吸成功治疗,但12例患者(39%)需要进一步的急诊手术干预。住院并发症包括死亡(42%)、急诊手术(39%)、心肌梗死(29%)和输血(65%)。心脏压塞是PCI中一种罕见但重要的并发症,与高死亡率和高发病率相关。大多数病例在导管室被识别,但延迟性心脏压塞可能发生,必须被视为PCI后晚期低血压的一个原因。